Australia is anticipating the availability of Retatrutide, a novel medication by Novo Nordisk. This dual-action drug, targeting both GLP-1 and GIP receptors, has shown significant efficacy in testing, implying a https://bookmarkpath.com/story21949304/this-new-drug-retatrutide-australia-a-promising-hope-for-obesity-treatment